Why Edgewise Therapeutics Stock Rocked the Market Today [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
10 stocks we like better than Edgewise Therapeutics › Edgewise Therapeutics (NASDAQ: EWTX) had some rather good news to report from the lab, and investors welcomed it on Wednesday. On that considerable tailwind, the biotech 's share price surged nearly 26% higher on the last trading day before Christmas. That morning, Edgewise presented interim data from its ongoing Phase 2 clinical trial of EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). This is a genetic heart condition in which the heart's muscle thickens, affecting its ability to pump blood throughout the body. Edgewise found that, in the B and C parts of the trial, evidence of clinical activity was detected across significant HCM disease markers. Additionally, the drug maintained a favorable safety profile and was generally well-tolerated. The current part D of the trial is a 12-week study, and Edgewise said that over 40 participants are enrolled in the trial. As of Dec. 23, the healthcare
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic CardiomyopathyPR Newswire
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR Newswire
- Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EWTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors [Yahoo! Finance]Yahoo! Finance
EWTX
Earnings
- 11/6/25 - Beat
EWTX
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 3
- 11/20/25 - Form 8-K
- EWTX's page on the SEC website